Replies to post #100193 on Biotech Values

[rkrw]

They've slashed their costs to fairly low levels and hired Lazard. I did hear their June funding was 3X oversubscribed and it would anger the investors who went in terribly if they raised again so quickly. I'd give it a 2-3 more quarters before they need to consider raising vs the timing of a transaction (or not).
Just an opinion, I could be wrong.